Onkologie. 2015:9(5):251-254

¨ESMO 2015: Co nového v léčbě mCRC

Jan Bauer

Zveřejněno: 1. prosinec 2015  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bauer J. ¨ESMO 2015: Co nového v léčbě mCRC. Onkologie. 2015;9(5):251-254.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobrazit celý článek

    Reference

    1. Hahn S, et al. Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first-line anti-EGFR therapy selection. ESMO, 2015, abstract No. 402. Přejít k původnímu zdroji...
    2. Jones FS, et al. Blood based detection of RAS mutations to guide anti-EGFR therapy in metastatic CRC patients: Concordance of results from circulating tumor DNA and tissue-based RAS testing. ESMO 2015, poster No. 2012. Přejít k původnímu zdroji...
    3. Scott R, et al. Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing. Ann Oncol. 2015;26: Suppl 4, abstract P-273. Přejít k původnímu zdroji...
    4. Siravegna G, et al. Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. J Clin Oncol 33, 2015 (suppl; abstr 11073). Přejít k původnímu zdroji...
    5. Heinemann V, et al.: A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2015;26: Suppl 4, abstract PD-013. Přejít k původnímu zdroji...
    6. Tamburini E, et al. Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials. J Clin Oncol 33:5s, 2015 (suppl; abstr e14634). Přejít k původnímu zdroji...
    7. Khattak MA, et al.: Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. Clinical Colorectal Cancer 2015; Vol. 14 (2): 81-90. Přejít k původnímu zdroji... Přejít na PubMed...
    8. Pietrantonio F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2015 Jun 5. pii:S1040-8428(15)00114-6. Přejít k původnímu zdroji...
    9. Aranda E, et al. Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: TheMACRO-2 trial. ESMO 2015, abstract (poster) 2122. Přejít k původnímu zdroji...
    10. Cremolini C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 2015; 26(6): 1188-1194. Přejít k původnímu zdroji...
    11. Heinemann V, et al. Ann Oncol, 2014; 25(2): abstr. O-0030.
    12. Douilard JY, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer 2015; 51: 1231-1242. Přejít k původnímu zdroji...
    13. Rivera F, et al. Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC. ESMO 2015, abstract No. 2014. Přejít k původnímu zdroji...
    14. Cheng Al, et al. Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI + cetuximab once every 2 weeks in the APEC study. ESMO 2015, abstract No. 2112. Přejít k původnímu zdroji...
    15. Abad A, et al. Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). ESMO 2015, abstract No. 2128. Přejít k původnímu zdroji...
    16. Souglakos J, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)British Journal of Cancer 2006; 94: 798-805. Přejít k původnímu zdroji... Přejít na PubMed...
    17. Falcone A, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord OvestJ Clin Oncol 2007; 25: 1670-1676. Přejít k původnímu zdroji... Přejít na PubMed...
    18. Masi G, et al. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. J Natl Cancer Inst 2011; 103: 21-30. Přejít k původnímu zdroji... Přejít na PubMed...
    19. Ychou M, et al.: A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 2013; 20(13): 4289-4297. Přejít k původnímu zdroji...
    20. Cremolini C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Ann Oncol. 2015; 26: Suppl 4, abstract LBA-09. Přejít k původnímu zdroji...
    21. Gruenberger T, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26(4): 702-708. Přejít k původnímu zdroji...
    22. Yanhong Deng, et al. Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study). J Clin Oncol 33, 2015 (suppl 3; abstr TPS798). Přejít k původnímu zdroji...
    23. Martens U, et al. An open-label 2:1 randomized phase I/II study of Panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients with non-resectable metastatic colorectal cancer and ras wild type (VOLFI / AIO-KRK-0109). ESMO 2015., abstract No. 2049. Přejít k původnímu zdroji...

    Zpět na obsah